-
Novel food information: Canola (Brassica napus) Event CLB-1
Health Canada has notified BASF Canada that it has no objection to the sale of food derived from herbicide tolerant canola CLB-1 BN02-131. The Department conducted a... -
Radiation surveillance program
Radiation is a part of Canada's environment. We have several measurement programs in place to protect the health of Canadians by continually monitoring natural and man-made... -
Standing Committee on Health
Briefing packages for Minister and Deputy Ministers’ Parliamentary Committee appearances. Appearance of the Deputy Minister of Health before the Standing Committee on Health on... -
Notice: Guidance Document: Post-Drug Identification Number (DIN) Changes
This guidance document applies to drugs regulated under Part C, Division 1 of the Regulations that have received a DIN pursuant to Section C.01.014.2. This includes... -
Consultation: Guidelines for Canadian drinking water quality: Operational parameters
This guideline technical document outlines the evaluation of the available information on calcium, magnesium, hardness, chloride, sulphate, total dissolved solids (TDS) and... -
Notice - Publication of information about certain Clinical Trial...
This Notice serves to inform clinical trial sponsors that Health Canada will publish information about all clinical trial applications (CTAs) authorized as of April 1, 2013, for... -
Natural health products international activities
To help facilitate the free-flow of natural health products across Canada's borders, Health Canada has established several Mutual Recognition Agreements (MRAs) and Memoranda of... -
Summary Safety Review - Dipeptidylpeptidase-4 (DPP-4) Inhibitors - Assessing...
A safety review was carried out by Health Canada to evaluate the increased risk of heart failure with the use of DPP-4 inhibitors as a follow-up to a risk communication released... -
Proposed Registration Decision PRD2020-06, Broflanilide, Cimegra, Teraxxa...
This summary describes the key points of the evaluation, while the Science Evaluation of Proposed Registration Decision PRD2020-06, Broflanilide, Cimegra, Teraxxa and Teraxxa F4... -
Amendments to the Hazardous Products Regulations
On January 4, 2023, Health Canada published amendments to the Hazardous Products Regulations (HPR) in the Canada Gazette, Part II. The regulatory amendments provide a 3-year... -
COVID-19 vaccinated travellers entering Canada
Fully vaccinated foreign nationals will be allowed to enter Canada for discretionary travel on specific dates. -
Consumer Product Enforcement Summary Report: Cyclical Enforcement Project...
The purpose of this Cyclical Enforcement (CE) project was to verify industry's compliance of corded window covering products with specific requirements of the Corded Window... -
Notice - Prescription Drug List (PDL): Hydrocortisone
The purpose of this Notice of Amendment is to announce the revised listing for hydrocortisone on the Prescription Drug List (PDL). -
Proposed Special Review Decision PSRD2021-02, Special Reviews: Potential...
Before making a final decision on the special reviews of clothianidin, thiamethoxam and imidacloprid used on cucurbits and their potential risk to squash bees, Health Canada... -
Guidance Document: Use of a Foreign-sourced Reference Product as a Canadian...
To provide sponsors of an Abbreviated New Drug Submission or an Abbreviated Extraordinary Use New Drug Submission who are seeking to demonstrate pharmaceutical equivalence and... -
Cristobalite and quartz
Questions and answers regarding the uses of cristobalite and quartz and actions taken to protect the public and the environment. -
Acute Care During Extreme Heat: Recommendations and Information for Health...
Recognize heat illnesses and heat sensitive diseases. -
Natural health products legislation and guidelines
In Canada, natural health products (NHP's) fall under the Natural Health Products Regulations of the Food and Drugs Act. These Regulations came into effect on January 1, 2004.... -
Canada’s regulatory approach to drugs for rare diseases: orphan drugs
Canada's regulatory approach: Drugs for rare diseases are authorized for sale in Canada under the Food and Drugs Act and Part C of the Food and Drug Regulations. -
Guidance Document - Medical device licence renewal and fees for the right to...
This document provides guidance on how the fee for the right to sell medical devices will be administered in accordance with the Food and Drugs Act and as stipulated in the Fees...
Vous pouvez également accéder à ce catalogue en utilisant l'API (cf. Documentation de l'API).